Management of allergic reactions to oxaliplatin in colorectal cancer patients

Journal of Supportive Oncology

Volumn 6, Issue 8, 2008, Pages 373-378

  Suenaga, Mitsukuni ^a,b   Mizunuma, Nobuyuki ^a,b   Shinozaki, Eiji ^a,b   Matsusaka, Satoshi ^a,b   Chin, Keisho ^a,b   Muto, Tetsuichiro ^a,b   Konishi, Fumio ^a,b   Hatake, Kiyohiko ^a,b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD PRESSURE; CANCER PATIENT; CHILL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PATIENT CARE; PRIMARY PREVENTION; PRURITUS; QUALITY OF LIFE; SIDE EFFECT; SKIN MANIFESTATION; SKIN REDNESS; SWEATING; URTICARIA; COLORECTAL TUMOR; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 59449087371     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. André T, Bensmaine MA, Louvet C, et al. Multicentric phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
2. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
3. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
4. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998;34:1297-1298.
7. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin. Br J Cancer 2003;89:477-481.
8. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
9. Maindrault-Goebel F, André T, Tournigand C, et al. Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer 2005;41:2262-2267.
10. Cleare MJ, Hughes EG, Jacob B, Pepys J. Immediate (type I) allergic responses to platinum compounds. Clin Allergy 1976;6:183-195.
11. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97:2301-2307.
12. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253-262.
13. Goldberg A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996;98:841-843.
14. Wiesenfeld M, Reiders E, Corder M, Yoo TJ, Dietz B, Lovett J. Successful retreatment with cis-dichlorodiammineplatinum (II) after apparent allergic reactions. Cancer Treat Rep 1979;63:219-221.
15. Shleback AA, Clark PI, Green JA. Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 1995;35:349-351.
16. Planner RS, Weerasiri T, Timmins D, Grant P. Hypersensitivity reaction to carboplatin. J Natl Cancer Inst 1991;83:1763-1764.
17. Morgan J S, Adams M, Ma s o n MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 1994;30A:1205-1206.
18. Weidemann B, Mülleneisen N, Bojko P, Niederle N. Hypersensitivity reactions to carboplatin. Cancer 1994;73:2218-2222.
19. Markman M, Kennedy A, Webster KM, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141-1145.
20. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466-469.
21. Stahl M, Köster W, Wilke H. Reaction after oxaliplatin-prevention with corticosteroids? Ann Oncol 2001;12:874.
22. Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000;11:497.
23. Hofheinz RD, Nguyen XD, Buchheidt, Kerowgan M, Hehlmann R, Hochhaus A. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol 2004;53:276-277.
24. Santini D, Tonini G, Salerno A, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12:132-133.
25. Newman Taylor AJ, Cullinan P, Lympany PA, Harris JM, Dowdeswell RJ, du Bois RM. Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Resp Crit Care Med 1999;160:435-438.
26. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30:5-13.
27. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546-549.
28. National Cancer Institute Common Terminology Criteria for Adverse Events. Version 3. Available at http://ctep.cancer.gov/forms/ CTCAEv3.pdf. Accessed October 15, 2008.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the united States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
30. Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006;17:259-261.